Apr 9, 2019
Genetically-engineered animal models (GEMs) are critical tools for drug discovery and development, but intellectual property (IP) concerns can complicate access.
As pharma and biotech increasingly outsource R&D activities to universities, careful scrutiny is required to ensure adherence to IP restrictions on research tools across those collaborative activities. As demonstrated by recent high-profile lawsuits, the stakes are higher than ever for all parties.
Despite improvements to in vitro assays, animal models are a critical part of preclinical drug discovery and development and will remain so for the foreseeable future. In particular, GEMs are specialised reagents with value across R&D stages.
Original article by Dr Megan M. MacBride
If you'd like to view the original article then follow the link below:
You can also download the original article pdf here:
For more information on Drug Discovery World, head to: